Clinical Trials Logo

Clinical Trial Summary

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas


Clinical Trial Description

Patients with EBV-associated lymphomas have inferior outcomes with standard-of-care therapies compared to those with EBV-negative disease. Nanatinostat is a selective class I HDAC inhibitor which induces EBV lytic phase protein generation, activating (val)ganciclovir to its cytotoxic form. This open-label, multicenter, multinational, single-arm, Phase 2 basket study employs a Simon's 2-stage design to allow termination of enrollment into cohorts where treatment appears futile, and will include the following cohorts of patients with EBV+ relapsed/refractory lymphomas: 1. EBV+ diffuse large B-cell lymphoma (DLBCL, NOS) 2. Peripheral T-cell lymphoma (PTCL), including PTCL-NOS and AITL 3. Post-transplant lymphoproliferative disorder (PTLD) 4. EBV+ lymphoproliferative disorders other than the above, including Extranodal NK/T-cell lymphoma (ENKTL) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05011058
Study type Interventional
Source Viracta Therapeutics, Inc.
Contact Strait Hicklin
Phone 858-400-8470
Email ClinicalTrials@Viracta.com
Status Recruiting
Phase Phase 2
Start date May 28, 2021
Completion date December 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04796857 - Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL Phase 1/Phase 2
Recruiting NCT05583149 - Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas Phase 2
Recruiting NCT04476459 - Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL Phase 1/Phase 2
Recruiting NCT04705129 - Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL Phase 2
Recruiting NCT04181489 - Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS Phase 2
Recruiting NCT04058470 - Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Phase 1/Phase 2
Recruiting NCT05544019 - Study of SGR-1505 in Mature B-Cell Neoplasms Phase 1